

Attribution of non-ClinicalTrials.gov registries among WHO International Clinical Trials
Registry Platform-registered trials from 2014 to 2018: A protocol for a meta-epidemiological
study

Masahiro Banno^{1,2}, Yasushi Tsujimoto^{3,4}, Yuki Kataoka^{5,6}

¹ Department of Psychiatry, Seichiryo Hospital, Nagoya City, Aichi Prefecture, Japan

² Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya City,
Aichi Prefecture, Japan

³ Department of Healthcare Epidemiology, School of Public Health in the Graduate School of
Medicine, Kyoto University, Kyoto City, Kyoto Prefecture, Japan

⁴ Department of Nephrology and Dialysis, Kyoritsu Hospital, Kawanishi City, Hyogo Prefecture,
Japan

⁵ Hospital Care Research Unit, Hyogo Prefectural Amagasaki General Medical Center,
Amagasaki City, Hyogo Prefecture, Japan

⁶ Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center,
Amagasaki City, Hyogo Prefecture, Japan

Corresponding author:

Masahiro Banno^{1,2}

Email address: solvency@med.nagoya-u.ac.jp

Author name abbreviations: Masahiro Banno (MB), Yasushi Tsujimoto (YT), Yuki Kataoka (YK)

23 **ABSTRACT**

24 **Background.** The attribution of non-ClinicalTrials.gov registries among registered trials of the
25 World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) had
26 increased until 2013. However, the attribution after 2013 is unknown. Moreover, no study has
27 investigated the usage of non-ClinicalTrials.gov registries after 2015 or compared the
28 characteristics of trials under non-ClinicalTrials.gov and ClinicalTrials.gov registries.

29 **Methods.** This will be a meta-epidemiological study. It will include all trials registered on the
30 ICTRP from January 1, 2014, to December 31, 2018. First, we will describe the total attribution
31 of non-ClinicalTrials.gov registries among the ICTRP-registered trials for each year and each
32 registry worldwide. Second, we will compare the recruitment status, target sample size, study
33 type, countries, retrospective registration, funding, and study phase of the trials on
34 ClinicalTrials.gov and other registries from 2014 to 2018. Third, we will report on the
35 distribution of primary registries of trials from the top five countries in order of the quantity of
36 registered trials on the ICTRP. We will separately report the results from interventional and other
37 studies. Inclusion criteria for interventional studies will be studies that include the word
38 “intervention” or “interventional” in “study type” of the data set. Other studies will refer to
39 studies other than interventional studies such as cohort, case-control, and cross-sectional studies.

40 **Ethics & Dissemination.** Ethics approval is not required for this study. This protocol has been
41 registered in the University Hospital Medical Information Network Clinical Trials Registry
42 (UMIN-CTR). The findings will be published in a peer-reviewed journal and may be presented at
43 conferences.

44 **Trial Registration Number.** UMIN000034401

Introduction

It is important to register clinical trials in order to avoid waste from inaccessibility of information on study methods and reduced publication bias, both of which may affect patient care and research (Chalmers & Glasziou, 2009; Chan et al., 2014). Over a decade, the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) has developed as a registry and collected data of trials in national and regional registries all over the world since 2005 (Gulmezoglu et al., 2005; WHO International Clinical Trials Registry Platform (ICTRP), 2018). ClinicalTrials.gov was the largest of the 16 registries that supplied data to the ICTRP until 2013 (Viergever & Li, 2015) and had 119,840 records of drug trials before July, 2015 (Zwierzyna et al., 2018).

Attribution of non-ClinicalTrials.gov registries among ICTRP-registered trials had increased from 30% to 50% between 2005 and 2013 (Viergever & Li, 2015). It might have been because of the small annual growth rate of medical research funding in the USA from 2004 to 2011 as compared to the global annual growth rate as the non-USA share of global medical research funding increased from 43% to 56% between 2004 and 2012 (Moses et al., 2015). The attribution of non-ClinicalTrials.gov registries among ICTRP-registered trials is expected to further increase because another study (Zwierzyna et al., 2018) has reported a recent decrease in attribution of trials registered in the USA on ClinicalTrials.gov, which might be derived from a shift in which are officially the largest countries in terms of the number of registered trials for a decade (ClinicalTrials.gov is under the control of the USA). However, the current status of the attribution of non-ClinicalTrials.gov registries among ICTRP-registered trials is unknown.

We hypothesize that the attribution of non-ClinicalTrials.gov registries among ICTRP-registered trials from 2014 to 2018 is higher than it previously was (from 2004 to 2013). This study will examine the attribution of non-ClinicalTrials.gov registries among ICTRP-registered trials from 2014 to 2018. We will investigate not only interventional studies, but also other studies registered in the ICTRP. Non-interventional studies registered on ClinicalTrials.gov are receiving a lot attention and no study has investigated non-interventional studies registered on the ICTRP (Baudart et al., 2016; Boccia et al., 2016).

Study Objectives

The primary purpose of this study is to investigate the total attribution of worldwide non-ClinicalTrials.gov registries among ICTRP-registered trials each year. The secondary objectives are to a) compare the characteristics of registered trials on ClinicalTrials.gov and other registries among the ICTRP from 2014 to 2018 and b) describe the distribution of primary registries of trials from the top five countries, in order of the quantity of registered trials on the ICTRP. We will separately report the results from interventional and other studies.

Materials & Methods

Types of Studies to be Included

All trials registered on the ICTRP from January 1, 2014, to December 31, 2018, will be included in the data set. We will divide trials into interventional studies and other studies. The inclusion criteria for interventional studies will be studies that include the word “intervention” or “interventional” in “study type” of the data set. Other studies will refer to studies other than

interventional studies such as cohort, case-control, and cross-sectional studies (Boccia et al., 2016).

Search Methods

A search of the ICTRP will be conducted in March 2019, for all trials registered from January 1, 2014, to December 31, 2018.

About the Data Set

This study will use data downloaded from the ICTRP data set available on the server of the WHO. The following fields will be extracted: TrialID, Study_type, Study_design, Phase, Date_registration, Target_size, Recruitment_Status, Primary_sponsor, Secondary_sponsors, Source_Support, Countries, Bridged_type and Retrospective_flag.

Data Analysis

First, the total attribution of non-ClinicalTrials.gov registries among ICTRP-registered trials for each year from 2014 to 2018 will be described. We will calculate the total attribution of non-ClinicalTrials.gov registries among the ICTRP-registered trials, dividing the number of registered trials in non-ClinicalTrials.gov registries by the number of total registered trials on the ICTRP. The Cochran-Armitage test will be performed to examine attribution trends.

Second, the attribution of each non-ClinicalTrials.gov registry among the ICTRP-registered trials for each year from 2014 to 2018 will be described. This will be carried out in the same manner as described above.

Third, the study will report on the recruitment status, target sample size, study type, countries, retrospective registration (Yes, No), funding (Yes, No), and study phase of the trials on ClinicalTrials.gov and other registries between 2014 and 2018. We will record a “Yes” for retrospective registration if retrospective_flag is found to be “1,” and a “No” if retrospective_flag is found to be “NULL” or unclear. We will record a “Yes” for funding if source_support has any description of the funders, and a “No” if source_support has no descriptions of any funders (for example, empty, none, no funder, and so on).

Fourth, the distribution of primary registries of trials from the top five countries, in order of the quantity of registered trials on the ICTRP, will be reported on.

Sensitivity analysis

We will perform default analyses including duplications because we believe that discrete records for the same trial may include a slightly different description about a trial and because recognizing the individuality of all the registered records is important. Duplications occur when researchers register one trial in different registries or when they register one trial in the same registry more than once (van Valkenhoef, Loane & Zarin, 2016). We will perform a sensitivity analysis excluding duplications for the registered trials. We will exclude duplications in such a way that we will delete the records, which are input as “Child” in “Bridged_type.”

Ethics & Dissemination

Since this will be a meta-epidemiological study, an ethics approval is not required. The protocol used has been registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) (Trial registration number: UMIN000034401). The

planned completion date of the present study is December 31, 2019. The findings will be published in a peer-reviewed journal and may be presented at conferences.

Discussion

Strengths

To conduct a systematic review, authors are encouraged to search ongoing and unpublished studies that are registered on the ICTRP (Higgins & Green, 2011). However, a previous study has reported that only 40% and 24% of authors searched ClinicalTrials.gov and the ICTRP, respectively (Baudard et al., 2017). We hypothesize that more non-ClinicalTrials.gov registries have been attributed to the ICTRP since 2014. The results are expected to prove that a mere search on ClinicalTrials.gov is not sufficient, and to highlight the importance of searching the ICTRP to identify ongoing and unpublished studies. Moreover, this study will compare the characteristics of registered trials on ClinicalTrials.gov and other registries. The results of the third analysis will suggest improvements for the registries. For example, many studies have pointed out a considerable number of retrospective registrations that may cause bias in estimation of treatment effect (Huic, Marusic & Marusic, 2011; Viergever et al., 2014; Scott, Rucklidge & Mulder, 2015; Viergever & Li, 2015; Harriman & Patel, 2016; Zarin et al., 2017). We will show and compare the proportion of retrospective registrations across the registries on the ICTRP. This may highlight implications for further research and help improve the registries. Furthermore, this study will mention the registries and countries that researchers should preferentially investigate, reflecting the top five countries in order of the quantity of registered trials on the ICTRP.

159

160 Limitations

161 The applicability of this study will be limited because the data include only trials registered on
 162 the ICTRP. The registry has a representative data set of trials (WHO International Clinical Trials
 163 Registry Platform (ICTRP), 2018). However, other, possibly low-quality, registered data of trials
 164 may be excluded. For example, trials registered in the South African National Clinical Trials
 165 Register (SANCTR) will be excluded (WHO International Clinical Trials Registry Platform
 166 (ICTRP), 2018). It is expected that the exclusion of the SANCTR will have an insignificant
 167 impact on the overall results. All countries in Africa that join in the African Vaccine Regulatory
 168 Forum have agreed to regard the Pan African Clinical Trials Registry (PACTR), which supplies
 169 data to the ICTRP, as their primary registry (WHO International Clinical Trials Registry Platform
 170 (ICTRP), 2018).

171

172 Acknowledgements

173 We would like to thank the WHO for managing the ICTRP. We would also like to thank
 174 Editage (www.editage.jp) for their English language editing services.

175

176 Author Contributions

177 All authors (MB, YT, and YK) have contributed to the conception and design of the research.
 178 MB was solely responsible for writing the protocol. All authors gave their final approval of the
 179 protocol before submission. It has been planned that after the publication of the protocol, MB,
 180 YT, and YK will screen the relevant records of the ICTRP, extract data, conduct the data analysis
 181 without being blind to the data, and write the manuscript.

182

183 **Declaration of Competing Interests**

184 Masahiro Banno has received speaker honoraria from Dainippon Sumitomo and travel fees
185 from Yoshitomi Pharmaceutical Industries Ltd. The other authors have no competing interests to
186 declare.

187

188 **Funding Statement**

189 This work was supported by the Department of Respiratory Medicine, Hyogo Prefectural
190 Amagasaki General Medical Center, and the Nagoya University Academy of Psychiatry. The
191 aforementioned funders played no role in developing the protocol. Self-funding was also
192 involved.

193

References

- Baudard M, Yavchitz A, Ravaud P, Perrodeau E, Boutron I. 2017. Impact of searching clinical trial registries in systematic reviews of pharmaceutical treatments: methodological systematic review and reanalysis of meta-analyses. *The BMJ* 356:j448 DOI: 10.1136/bmj.j448
- Baudart M, Ravaud P, Baron G, Dechartres A, Haneef R, Boutron I. 2016. Public availability of results of observational studies evaluating an intervention registered at ClinicalTrials.gov. *BMC medicine* 14:7 10.1186/s12916-016-0551-4
- Boccia S, Rothman KJ, Panic N, Flacco ME, Rosso A, Pastorino R, Manzoli L, La Vecchia C, Villari P, Boffetta P, Ricciardi W, Ioannidis JP. 2016. Registration practices for observational studies on ClinicalTrials.gov indicated low adherence. *Journal of clinical epidemiology* 70:176-182 10.1016/j.jclinepi.2015.09.009
- Chalmers I, Glasziou P. 2009. Avoidable waste in the production and reporting of research evidence. *Lancet* 374:86-89 DOI: 10.1016/S0140-6736(09)60329-9
- Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gotzsche PC, Krumholz HM, Gherzi D, van der Worp HB. 2014. Increasing value and reducing waste: addressing inaccessible research. *Lancet* 383:257-266 DOI: 10.1016/S0140-6736(13)62296-5
- Gulmezoglu AM, Pang T, Horton R, Dickersin K. 2005. WHO facilitates international collaboration in setting standards for clinical trial registration. *Lancet* 365:1829-1831 DOI: 10.1016/S0140-6736(05)66589-0
- Harriman SL, Patel J. 2016. When are clinical trials registered? An analysis of prospective versus retrospective registration. *Trials* 17:187 DOI: 10.1186/s13063-016-1310-8

- 216 Higgins J, Green S. 2011. Cochrane Handbook for Systematic Reviews of Interventions Version
217 5.1.0 [updated March 2011]. Available at <http://handbook-5-1.cochrane.org/> (accessed 25
218 October 2018).
- 219 Huic M, Marusic M, Marusic A. 2011. Completeness and changes in registered data and
220 reporting bias of randomized controlled trials in ICMJE journals after trial registration
221 policy. *PLoS One* 6:e25258 DOI: 10.1371/journal.pone.0025258
- 222 Moses H, 3rd, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. 2015. The
223 anatomy of medical research: US and international comparisons. *JAMA* 313:174-189
224 DOI: 10.1001/jama.2014.15939
- 225 Scott A, Rucklidge JJ, Mulder RT. 2015. Is Mandatory Prospective Trial Registration Working to
226 Prevent Publication of Unregistered Trials and Selective Outcome Reporting? An
227 Observational Study of Five Psychiatry Journals That Mandate Prospective Clinical Trial
228 Registration. *PLoS One* 10:e0133718 DOI: 10.1371/journal.pone.0133718
- 229 van Valkenhoef G, Loane RF, Zarin DA. 2016. Previously unidentified duplicate registrations of
230 clinical trials: an exploratory analysis of registry data worldwide. *Systematic reviews*
231 5:116 10.1186/s13643-016-0283-8
- 232 Viergever RF, Karam G, Reis A, Gherzi D. 2014. The quality of registration of clinical trials: still
233 a problem. *PLoS One* 9:e84727 DOI: 10.1371/journal.pone.0084727
- 234 Viergever RF, Li K. 2015. Trends in global clinical trial registration: an analysis of numbers of
235 registered clinical trials in different parts of the world from 2004 to 2013. *BMJ Open*
236 5:e008932 DOI: 10.1136/bmjopen-2015-008932
- 237 WHO International Clinical Trials Registry Platform (ICTRP). 2018. Available at
238 <http://www.who.int/ictip> (accessed 25 October 2018).

239 Zarin DA, Tse T, Williams RJ, Rajakannan T. 2017. Update on Trial Registration 11 Years after
240 the ICMJE Policy Was Established. *The New England journal of medicine* 376:383-391
241 DOI: 10.1056/NEJMSr1601330

242 Zwierzyna M, Davies M, Hingorani AD, Hunter J. 2018. Clinical trial design and dissemination:
243 comprehensive analysis of clinicaltrials.gov and PubMed data since 2005. *The BMJ*
244 361:k2130 DOI: 10.1136/bmj.k2130

245